By Ilan Zipkin
Staff writer

Although a consortium of big pharma companies is reportedly nearing completion of their long-anticipated agreement to build a public database of single nucleotide polymorphisms, SNP data inevitably was destined to become a commodity. The competitive playing field ultimately will be defined by the more difficult - and more value added - challenges of using the information in drug discovery and pharmacogenomics.